Abu Dhabi: «The Gulf»
Researchers from the Cleveland Clinic in the United States have begun a study of a vaccine aimed at preventing triple negative breast cancer, which is the most deadly form of the disease.
The trial, in its first phase, was designed to determine the maximum tolerable dose of the vaccine in patients with triple-negative breast cancer in its early stages, as well as to distinguish and improve the body’s immune response. Cleveland Clinic and Anexa Biosciences begin conducting the study.
Dr. J. Thomas Budd, of the Cleveland Clinic’s Tasseg Cancer Institute and lead author of the study, said he hopes this research study will lead to more advanced trials to determine the effectiveness of the vaccine against this highly aggressive form of breast cancer. The long-term goal is for this to become a real preventive vaccine given to women to prevent them from developing triple negative breast cancer, which is the most difficult form of this cancer to treat.”
“This vaccine represents a potentially new way to control breast cancer,” said Dr. Vincent Toohy, lead inventor of the vaccine and an immunologist at the Cleveland Clinic’s Lerner Research Institute.
The experimental vaccine targets the breast-feeding protein alpha-lactalbumin, which is absent after lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers, and immune system activation works against this “retired” protein.